ReviewTaiwan journal of ophthalmology
Restoring the mucin barrier: Advances in secretagogue therapies for ocular surface disorders.
Review in Taiwan journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Acute tear-film disruption in treatment-naive acute anterior uveitis: A retrospective case-control study.Medicine · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucins are essential components of the ocular surface, ensuring epithelial protection, tear film stability, and immune regulation. Mucin deficiency contributes to a spectrum of ocular surface disorders, including dry eye disease, allergic conjunctivitis, and cicatricial conditions such as Stevens-Johnson syndrome and ocular graft-versus-host disease. This review outlines current knowledge of mucin biology, regulatory mechanisms, and emerging therapeutic applications of mucin secretagogues in ocular surface disorders. Signaling cascades involving EGFR activation, MAPK phosphorylation, cholinergic and adrenergic stimulation, and cytokine-mediated modulation (e.g., interleukin-13, tumor necrosis factor-α) govern mucin transcription and goblet cell function. Clinically approved secretagogues such as diquafosol and rebamipide improve mucin expression and epithelial healing, while biologics, gene therapies, and nutraceutical compounds are actively being explored. Advancing these therapies may enable more targeted and durable restoration of ocular surface integrity across a range of mucin-deficient diseases. We searched for related research on PubMed using the terms "Mucin" and "Mucin secretagogues," along with keywords such as "dry eye," "goblet cell," and "ocular surface disorder." Articles related to mucin secretagogues published within the last 10 years were reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.